277
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

, ORCID Icon, ORCID Icon, , , , , , , ORCID Icon, , & show all
Pages 3014-3017 | Received 01 Jun 2020, Accepted 04 Jul 2020, Published online: 28 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Bahar Uncu Ulu, Mehmet Sinan Dal, İpek Yönal Hindilerden, Olga Meltem Akay, Özgür Mehtap, Nurhilal Büyükkurt, Fehmi Hindilerden, Ahmet Kürşad Güneş, Tuğçe Nur Yiğenoğlu, Semih Başcı, Merih Kızıl Çakar, Didar Yanardağ Açık, Serdal Korkmaz, Turgay Ulaş, Gülsüm Özet, Burhan Ferhanoğlu, Meliha Nalçacı & Fevzi Altuntaş. (2022) Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy 34:3, pages 190-198.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.